FDA Grants Full Approval to Imlunestrant-Abemaciclib for ESR1-Mutated Advanced Breast Cancer

The FDA granted full approval on September 18 to imlunestrant (Inluriyo) combined with abemaciclib (Verzenio) for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that progressed after at least one prior endocrine therapy. The combination is restricted to patients whose ESR1 mutation is confirmed by an FDA-authorized test.

The agency also approved Guardant360 CDx as the companion diagnostic for patient selection. Both agents are manufactured by Eli Lilly and Company.

For patients, the implications are narrow and specific. This is not a first-line option. It applies when hormone-blocking therapy has failed and a blood test reveals an acquired resistance mutation. Approximately half of patients with ER-positive, HER2-negative metastatic breast cancer develop an ESR1 mutation during or after aromatase inhibitor therapy.

The Trial Numbers Behind the Decision

Approval is based on EMBER-3, a randomized, open-label trial enrolling 874 adults previously treated with an aromatase inhibitor, with or without a CDK4/6 inhibitor. Participants were assigned to imlunestrant alone, investigator’s choice endocrine therapy, or imlunestrant plus abemaciclib.

The pivotal data come from an exploratory subgroup analysis of 159 patients with ESR1 mutations. Median progression-free survival was 11.1 months for the combination versus 5.5 months for imlunestrant alone (HR 0.53), with objective response rates of 35% versus 15%.

Two caveats deserve prominence. First, overall survival data were immature at the interim analysis, with deaths recorded in 35% of the ESR1-mutated subgroup, so the trial has not demonstrated a survival benefit. Progression-free survival reflects disease control, not overall survival. Second, the FDA noted that imlunestrant alone did not improve progression-free survival over standard endocrine therapy in the overall population or in patients without the mutation, indicating the benefit was restricted to those with the mutation.

Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center, principal investigator for EMBER-3, outlined the rationale in Lilly’s approval announcement. Combining agents targeting two distinct drivers of tumor growth—the estrogen receptor and CDK4/6—represents “an important strategy to help address treatment resistance,” she said. Memorial Sloan Kettering discloses that Jhaveri has financial interests related to Eli Lilly, and the trial was sponsored by the company.

A Blood Test Decides Who Qualifies

ESR1 mutation status in the trial was determined via circulating tumor DNA analysis from a blood sample rather than tissue biopsy. This matters for access: liquid biopsy is easier to repeat than surgical sampling, which is relevant because the mutation is typically acquired over time rather than present at diagnosis.

Patients whose disease is progressing on endocrine therapy may ask their oncologist whether ESR1 testing has been performed, when it was last done, and whether repeat testing is warranted. This is a question of eligibility rather than a request for a specific drug, and it determines whether this option is available.

Coverage remains uncertain for most patients. Both drugs are oral and typically fall under pharmacy benefits, where specialty-tier cost-sharing can be substantial. Patients facing denials can inquire about prior authorization, appeals, and manufacturer patient-assistance programs. Approval itself does not set a price or guarantee coverage.

Side Effects That Shape the Daily Reality of Treatment

The combination carries meaningful tolerability concerns. In EMBER-3, diarrhea occurred in 86% of patients receiving the combination, with grade 3 or 4 cases in 9%. Neutropenia occurred in 86%, with grade 3 or 4 decreases in 21%. Interstitial lung disease or pneumonitis occurred in 2.9%, and venous thromboembolic events in 4.8%.

Serious adverse reactions occurred in 21% of patients on the combination, and fatal reactions in 3.8%, including pneumonia, myocardial infarction, interstitial lung disease, and sepsis. Most adverse events were mild to moderate, and permanent discontinuation rates were low: 1% for imlunestrant and 3.4% for abemaciclib.

Monitoring is required: blood counts and liver function tests are checked before starting, every two weeks for the first two months, monthly for the next two months, and as clinically indicated. Both drugs carry embryo-fetal toxicity warnings, and effective contraception is advised during treatment and for a period afterward.

Imlunestrant is taken once daily on an empty stomach and abemaciclib twice daily until disease progression or unacceptable toxicity. Patients should report loose stools promptly, as starting antidiarrheal treatment, increasing fluids, and notifying the care team is standard.

This is the second FDA approval for imlunestrant in less than a year. The drug was cleared as a single agent in September 2025. Two weeks earlier, the FDA granted accelerated approval to camizestrant with a CDK4/6 inhibitor for a different setting: when a blood test detects an emerging ESR1 mutation during first-line therapy, before imaging shows progression. EMBER-4, a trial of more than 8,000 patients testing imlunestrant after surgery in early breast cancer, results are anticipated in 2027.

Key Questions Answered

Who is this approval for? Adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one prior endocrine therapy.

How is eligibility determined? Through an FDA-authorized test; the agency approved Guardant360 CDx as the companion diagnostic.

What did the trial show? Median progression-free survival of 11.1 months with the combination versus 5.5 months with imlunestrant alone in 159 patients with ESR1 mutations.

Does it help people live longer? Not established. Overall survival data were immature at interim analysis.

What are the most common side effects? Diarrhea and neutropenia, each in 86% of patients on the combination, plus reduced hemoglobin, nausea, fatigue, and other laboratory abnormalities.

Is this a first-line treatment? No. It is indicated after progression on at least one prior endocrine therapy.

What should patients ask their oncologist? Whether ESR1 testing has been performed, when, and whether repeat testing is appropriate, as the mutation is usually acquired during treatment.

Source link